News
Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label expansions to reduce the risk of cardiovascular issues. | Eli Lilly has presented phase 3 results showing its Mounjaro measures up to the company’s GLP-1 Trulicity in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease.
Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...
Lawmakers warn the arrangement Eli Lilly and Pfizer have with telehealth platforms may lead to conflicts of interest, subpar ...
This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. Eli Lilly's recent popularity is due in no small measure to its plunge into the highly ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.
We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company ...
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback